Habitual intake of dietary methylglyoxal is associated with less low-grade inflammation: the Maastricht Study.

Abstract

BACKGROUND:

Dicarbonyls are major reactive precursors of advanced glycation endproducts (AGEs). Dicarbonyls are formed endogenously and also during food processing. Circulating dicarbonyls and AGEs are associated with inflammation and microvascular complications of diabetes, but for dicarbonyls from the diet these associations are currently unknown.

OBJECTIVES:

We sought to examine the associations of dietary dicarbonyl intake with low-grade inflammation and microvascular function.

METHODS:

In 2792 participants (mean ± SD age: 60 ± 8 y; 50% men; 26% type 2 diabetes) of the population-based cohort the Maastricht Study, we estimated the habitual intake of the dicarbonyls methylglyoxal (MGO), glyoxal (GO), and 3-deoxyglucosone (3-DG) by linking FFQ outcome data to our food composition database of the MGO, GO, and 3-DG content of >200 foods. Low-grade inflammation was assessed as six plasma biomarkers, which were compiled in a z score. Microvascular function was assessed as four plasma biomarkers, compiled in a zscore; as diameters and flicker light-induced dilation in retinal microvessels; as heat-induced skin hyperemic response; and as urinary albumin excretion. Cross-sectional associations of dietary dicarbonyls with low-grade inflammation and microvascular function were investigated using linear regression with adjustments for age, sex, potential confounders related to cardiometabolic risk factors, and lifestyle and dietary factors.

RESULTS:

Fully adjusted analyses revealed that higher intake of MGO was associated with a lower z score for inflammation [standardized β coefficient (STD β): -0.05; 95% CI: -0.09 to -0.01, with strongest inverse associations for hsCRP and TNF-α: both -0.05; -0.10 to -0.01]. In contrast, higher dietary MGO intake was associated with impaired retinal venular dilation after full adjustment (STD β: -0.07; 95% CI: -0.12 to -0.01), but not with the other features of microvascular function. GO and 3-DG intakes were not consistently associated with any of the outcomes.

CONCLUSION:

Higher habitual intake of MGO was associated with less low-grade inflammation. This novel, presumably beneficial, association is the first observation of an association between MGO intake and health outcomes in humans and warrants further investigation.

• Authors: Kim Maasen, Simone J P M Eussen, Pieter C Dagnelie, Alfons J H M Houben, Carroll A B Webers, Miranda T Schram, Tos T J M Berendschot, Coen D A Stehouwer, Antoon Opperhuizen, Marleen M J van Greevenbroek, Casper G Schalkwijk
• Journal: The American journal of clinical nutrition (Am J Clin Nutr) Vol. 116 Issue 6 Pg. 1715-1728 (12 19 2022) ISSN: 1938-3207 [Electronic] United States
• PMID: 36055771 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of the American Society for Nutrition.

Chemical References

• Pyruvaldehyde
• Magnesium Oxide
• Glyoxal
• Glycation End Products, Advanced
• Biomarkers

Topics

• Male
• Humans
• Middle Aged
• Aged
• Female
• Pyruvaldehyde
• Diabetes Mellitus, Type 2
• Cross-Sectional Studies
• Magnesium Oxide
• Glyoxal
• Diet
• Inflammation
• Glycation End Products, Advanced
• Biomarkers
• Sexually Transmitted Diseases